Method of treatment using a therapeutic agent for intranasal administration

ABSTRACT

A method of intranasal treatment of nasal symptoms administered to a human in need of the treatment includes administering intranasally from an internasal spray container a composition having a therapeutically effective amount of  capsicum  extract to a human in need thereof; and effecting relief from at least one symptom. The symptom relieved includes at least one of nasal congestion, sinus pressure, headache, sinus pain or a combination thereof. The first relief of sinus pain, sinus pressure, or nasal decongestion in the human occurs within about 30 minutes of administration.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of and claims priority to U.S. patentapplication Ser. No. 14/082,890, filed Nov. 18, 2013, which is herebyincorporated by reference in its entirety for all purposes.

U.S. patent application Ser. No. 14/082,890 is a continuation of andclaims priority to U.S. patent application Ser. No. 13/234,862, filedSep. 16, 2011, now abandoned, which is herein incorporated by referencein its entirety for all purposes.

U.S. patent application Ser. No. 13/234,862 claim priority from U.S.Patent Application No. 61/405,390, filed Oct. 21, 2010, and is acontinuation-in-part of U.S. patent application Ser. No. 12/849,088,filed Aug. 3, 2010, which is a continuation of U.S. patent applicationSer. No. 11/731,657, filed Mar. 30, 2007, now abandoned, all of whichare herein incorporated by reference in their entirety for all purposes.This application is also related to U.S. patent application Ser. No.11/731,656, filed Mar. 30, 2007, now abandoned, which is hereinincorporated by reference in its entirety for all purposes.

FIELD OF THE INVENTION

The present invention relates to a method of treatment using atherapeutic agent capable of intranasal administration comprisingcapsicum and/or capsaicinoids as the therapeutic agent.

BACKGROUND OF THE INVENTION

Non-allergic rhinitis (“NAR”) affects millions of Americans, but themechanism(s) remains unknown. Transient receptor potential vanilloid-1(“TRPV1”) may be involved, as single dose studies of intranasalcapsaicin, a TRPV1 agonist, have demonstrated reduced nasal congestionin rhinitis subjects.

Chronic rhinitis is defined as persistent inflammation of the mucosalmembranes lining the nasal cavity, characterized by symptoms of nasalcongestion, rhinorrhea, sneezing and itching with or without post-nasaldrainage. (Settipane R A, Lieberman P. Update on nonallergic rhinitis.Ann Allergy Asthma Immunol 2001; 86:494-507; quiz-8. Wallace D V,Dykewicz M S, Bernstein D I, Blessing-Moore J, Cox L, Khan D A, et al.The diagnosis and management of rhinitis: an updated practice parameter.J Allergy Clin Immunol 2008; 122:S1-84.) A diagnosis requires theexclusion of structural abnormalities and underlying medical conditionsthat can manifest with rhinitis symptoms. (Settipane R A, Lieberman P.Update on nonallergic rhinitis. Ann Allergy Asthma Immunol 2001;86:494-507; quiz-8. Wallace D V, Dykewicz M S, Bernstein D I,Blessing-Moore J, Cox L, Khan D A, et al. The diagnosis and managementof rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122:S1-84.) Broadly defined, rhinitis can be divided into inflammatoryand non-inflammatory rhinitis. (Wallace D V, Dykewicz M S, Bernstein DI, Blessing-Moore J, Cox L, Khan D A, et al. The diagnosis andmanagement of rhinitis: an updated practice parameter. J Allergy ClinImmunol 2008; 122:S1-84. Bernstein J A. Characteristics of Non-AllergicRhintiis. World Allergy Journal 2009; 2:102-5.)

Inflammatory rhinitis includes seasonal or perennial allergic rhinitis,entopic rhinitis and non-allergic rhinitis eosinophilic syndrome(“NARES”) whereas non-inflammatory rhinitis includes vasomotor rhinitis(“VMR”), commonly referred to as idiopathic rhinitis, and othernon-allergic rhinitis conditions such as rhinitis medicamentosa,gustatory rhinitis and hormonally-induced rhinitis. (Bernstein J A.Characteristics of Non-Allergic Rhintiis. World Allergy Journal 2009;2:102-5. Kaliner M. Classification of Nonallergic Rhinitis SyndromesWith a Focus on Vasomotor Rhinitis, Proposed to be known henceforth asNonallergic Rhinopathy. World Allergy Journal 2009; 2:98-101.) Sincepatients with allergic rhinitis often exhibit significant symptoms inresponse to irritant triggers, clinicians have postulated that allergicand non-allergic rhinitis components often co-exist and have thereforereferred to this condition as “mixed rhinitis” (“MR”). (Bernstein J A,Rezvani, M. Mixed Rhinitis: A New Subclass of Chronic Rhinitis. in:Kaliner M, ed. Current Review of Rhinitis, 2nd ed 2006; Philadelphia,Pa.: 69-78.) Cross-sectional questionnaire survey studies have estimatedthat up to 75% of chronic rhinitis patients have either non-allergic ormixed rhinitis. (Settipane R A. Demographics and epidemiology ofallergic and nonallergic rhinitis. Allergy Asthma Proc 2001; 22:185-9.)

Currently non-allergic rhinitis (“NAR”) conditions are diagnoses byexclusion, as the mechanism(s) of this disorder is unknown andtherefore, there are no specific biomarkers or tests that establish adefinitive diagnosis. (Bernstein J A. Characteristics of Non-AllergicRhintiis. World Allergy Journal 2009; 2:102-5. Kaliner M. Classificationof Nonallergic Rhinitis Syndromes With a Focus on Vasomotor Rhinitis,Proposed to be known henceforth as Nonallergic Rhinopathy. World AllergyJournal 2009; 2:98-101. Brandt D, Bernstein J A. Questionnaireevaluation and risk factor identification for nonallergic vasomotorrhinitis. Ann Allergy Asthma Immunol 2006; 96:526-32. Garay R.Mechanisms of vasomotor rhinitis. Allergy 2004; 59 Suppl 76:4-9;discussion-10.) The most popular mechanism postulated for non-allergicrhinitis has been an autonomic imbalance between the sympathetic andparasympathetic nervous system resulting in parasympathetichyperactivity leading to nasal congestion and drainage. (Baraniuk J N.Sensory, parasympathetic, and sympathetic neural influences in the nasalmucosa. J Allergy Clin Immunol 1992; 90:1045-50. Jones A S. Autonomicreflexes and non-allergic rhinitis. Allergy 1997; 52:14-9.) Recently,transient receptor protein (“TRP”) ion channel activation leading totrigeminal nerve depolarization has been postulated to play an importantrole in NAR, as these ubiquitous receptors can be activated by differenttemperatures, chemicals, osmolality and other physical stimuli that arewell recognized triggers of symptoms in NAR patients. (Bernstein J A.Characteristics of Non-Allergic Rhintiis. World Allergy Journal 2009;2:102-5. Brandt D, Bernstein J A. Questionnaire evaluation and riskfactor identification for nonallergic vasomotor rhinitis. Ann AllergyAsthma Immunol 2006; 96:526-32. Seki N, Shirasaki H, Kikuchi M, SakamotoT, Watanabe N, Himi T. Expression and localization of TRPV1 in humannasal mucosa. Rhinology 2006; 44:128-34.)

Because mechanisms of NAR are poorly elucidated, there are still only afew medications approved for the treatment of this condition. Althoughclinical studies have found that the intranasal antihistamines,azelastine and olopatidine, intranasal ipratropium bromide andintranasal corticosteroids are relatively effective in relievingsymptoms related to NAR, it is unclear how they are mechanisticallyexerting their effect. (Banov C H, Lieberman P. Efficacy of azelastinenasal spray in the treatment of vasomotor (perennial nonallergic)rhinitis. Ann Allergy Asthma Immunol 2001; 86:28-35. Georgitis J W,Banov C, Boggs P B, Dockhorn R, Grossman J, Tinkelman D, et al.Ipratropium bromide nasal spray in non-allergic rhinitis: efficacy,nasal cytological response and patient evaluation on quality of life.Clin Exp Allergy 1994; 24:1049-55. Lieberman P L, Settipane R A.Azelastine nasal spray: a review of pharmacology and clinical efficacyin allergic and nonallergic rhinitis. Allergy Asthma Proc 2003;24:95-105. Scadding G K, Lund V J, Jacques L A, Richards D H. Aplacebo-controlled study of fluticasone propionate aqueous nasal sprayand beclomethasone dipropionate in perennial rhinitis: efficacy inallergic and non-allergic perennial rhinitis. Clin Exp Allergy 1995;25:737-43. Ciprandi G. Treatment of nonallergic perennial rhinitis.Allergy 2004; 59 Suppl 76:16-22; discussion-3.)

Capsaicin is a pungent substance found in capsicum spp. (red pepper)that is known to ablate sensory nerve fibers in NAR patients leadinginvestigators to postulate a role for afferent C-fibers in NAR. (Blom HM, Van Rijswijk J B, Garrelds I M, Mulder P G, Timmermans T, Gerth vanWijk R. Intranasal capsaicin is efficacious in non-allergic,non-infectious perennial rhinitis. A placebo-controlled study. Clin ExpAllergy 1997; 27:796-801.) This observation was supported by earlyplacebo controlled studies that treated NAR patients with topicalcapsaicin and found significant improvement in symptom scores comparedto placebo without changes in levels of mast cell mediators (i.e.,leukotrienes, prostaglandin (PGD2) or tryptase) indicating that theeffect of this medication was not due to reduction in mast-cell mediatedinflammation. (Blom H M, Van Rijswijk J B, Garrelds I M, Mulder P G,Timmermans T, Gerth van Wijk R. Intranasal capsaicin is efficacious innon-allergic, non-infectious perennial rhinitis. A placebo-controlledstudy. Clin Exp Allergy 1997; 27:796-801. Blom H M, Severijnen L A, VanRijswijk J B, Mulder P G, Van Wijk R G, Fokkens W J. The long-termeffects of capsaicin aqueous spray on the nasal mucosa. Clin Exp Allergy1998; 28:1351-8.)

Subsequently, it was discovered that capsaicin exerted its activitythrough activation of the TRP vanilloid-1 (“TRPV1”) ion channel whichleads to desensitization of nasal sensory neural fibers and reduction innasal hyperresponsiveness. (Seki N, Shirasaki H, Kikuchi M, Sakamoto T,Watanabe N, Himi T. Expression and localization of TRPV1 in human nasalmucosa. Rhinology 2006; 44:128-34.) Single intermittent short termdosing studies with intranasal capsaicin in AR and NAR have confirmedthat intranasal capsaicin is effective at reducing nasal congestion anddischarge. (Blom H M, Van Rijswijk J B, Garrelds I M, Mulder P G,Timmermans T, Gerth van Wijk R. Intranasal capsaicin is efficacious innon-allergic, non-infectious perennial rhinitis. A placebo-controlledstudy. Clin Exp Allergy 1997; 27:796-801. Blom H M, Severijnen L A, VanRijswijk J B, Mulder P G, Van Wijk R G, Fokkens W J. The long-termeffects of capsaicin aqueous spray on the nasal mucosa. Clin Exp Allergy1998; 28:1351-8. Lacroix J S, Buvelot J M, Polla B S, Lundberg J M.Improvement of symptoms of non-allergic chronic rhinitis by localtreatment with capsaicin. Clin Exp Allergy 1991; 21:595-600. Sanico A M,Philip G, Proud D, Naclerio R M, Togias A. Comparison of nasal mucosalresponsiveness to neuronal stimulation in non-allergic and allergicrhinitis: effects of capsaicin nasal challenge. Clin Exp Allergy 1998;28:92-100. Van Rijswijk J B, Boeke E L, Keizer J M, Mulder P G, Blom HM, Fokkens W J. Intranasal capsaicin reduces nasal hyperreactivity inidiopathic rhinitis: a double-blind randomized application regimenstudy. Allergy 2003; 58:754-61.)

However, the concentration of capsaicin used and found effective inthese studies, ranging from 30 ppm to 300 ppm, was very irritating andrequired a physician to co-administer a local anesthetic making itimpractical and intolerable for patients to self-administer thecomposition or use this treatment long term. (Blom H M, Van Rijswijk JB, Garrelds I M, Mulder P G, Timmermans T, Gerth van Wijk R. Intranasalcapsaicin is efficacious in non-allergic, non-infectious perennialrhinitis. A placebo-controlled study. Clin Exp Allergy 1997; 27:796-801.Blom H M, Severijnen L A, Van Rijswijk J B, Mulder P G, Van Wijk R G,Fokkens W J. The long-term effects of capsaicin aqueous spray on thenasal mucosa. Clin Exp Allergy 1998; 28:1351-8. Lacroix J S, Buvelot JM, Polla B S, Lundberg J M. Improvement of symptoms of non-allergicchronic rhinitis by local treatment with capsaicin. Clin Exp Allergy1991; 21:595-600. Van Rijswijk J B, Boeke E L, Keizer J M, Mulder P G,Blom H M, Fokkens W J. Intranasal capsaicin reduces nasalhyperreactivity in idiopathic rhinitis: a double-blind randomizedapplication regimen study. Allergy 2003; 58:754-61.) Applicant is notaware of any prior studies disclosing, teaching or suggesting acomposition comprising capsicum/capsaicin present in an effectiveconcentration, that may be self-administered as a mono-therapy by theuser. Furthermore, Applicant is not aware of any studies demonstratingclinical efficacy of capsicum/capsaicin at concentrations 10% or less ofthe dosages used in previous rhinitis clinical trials. What is needed inthe industry is a composition comprising capsicum/capsaicin that may beadministered intranasally in an effective concentration, allowing theuser to self-administer the composition without the need for the user tovisit a physician's office for each treatment.

According to an embodiment of the present invention, it has beenunexpectedly discovered that certain concentrations of capsicumcomprising capsaicinoids, including capsaicin, may be self-administeredby the user and provide relief from symptoms. Previously it has not beenpossible to deliver an effective concentration of capsicum intranasallywithout causing such discomfort to the user requiring the use of anadjunct to desensitize the nasal membranes in order to administer thecapsicum. What is needed in the industry is a composition comprisingcapsicum/capsaicin that is effective in relieving symptoms, but can beused without causing discomfort to the user or requiring adjunct agents.

Applicant is not aware of any prior studies investigating the immediateor short-term relief of symptoms provided by the intranasaladministration of capsicum as disclosed in the present application. Inaddition, Applicant is not aware of any prior studies disclosing that alow homeopathic dilution of capsicum is clinically effective for thetreatment of rhinitis.

What is needed in the industry is a nasally administered compositionthat provides a rapid onset of relief for rhinitis subjects. What isneeded in the industry is an intranasally administered compositionhaving a rapid onset of action and significant reduction of symptoms,that is an attractive mono-therapy or adjunctive therapy for themanagement of rhinitis symptoms, including, but not limited to, chronicrhinitis symptoms. What is needed in the industry is an intranasallyadministered composition having a quick onset of action with an averagetime to first relief in less than thirty minutes, less than fiveminutes, and even less than one minute.

Currently available over the counter (“OTC”) medicated nasal sprays forthe relief of rhinitis symptoms necessarily contain labels with awarning indicating that the product should not be used for more thanthree days. Extended use of these known products leads to the occurrenceof rebound congestion and the potential for addiction. These known OTCproducts are not suitable for use by those with symptoms that lastlonger than three days, including those suffering chronic conditions,and those suffering from chronic rhinitis symptoms.

What is needed in the industry is an intranasally administeredcomposition that is well-tolerated with prolonged treatment results andwith substantially no alteration or impairment in olfaction. What isneeded in the industry is an intranasal composition wherein usersexperience little to no rebound congestion. What is needed in theindustry is an intranasal composition wherein use of the compositionresults in an improvement in olfaction versus placebo after continueduse.

What is needed in the industry is an intranasally administeredcomposition wherein during a treatment period is significantly effectiveat improving nasal congestion, sinus pressure, sinus pain and headachecompared to placebo. What is needed in the industry is a nasallyadministered composition that provides safe, sustained relief over thecourse of a treatment period. What is needed in the industry is anasally administered composition that works fast and is safe.

What is needed in the industry is an intranasally administeredcomposition that provides relief from at least one of nasal congestion,sinus pressure and sinus pain with an improved therapeutic response thatcontinues over time with nasal congestion, sinus pressure, sinus painand headache significantly improved at about 5, 10, 15 and 30 minutesand persists for nasal congestion and sinus pain through the longesttime point measured.

SUMMARY OF THE INVENTION

An embodiment of the present invention is a composition comprising anaqueous homeopathic dilution of capsicum, wherein the composition issuitable for intranasal administration to a human in need thereof, thatprovides fast relief, wherein the first relief from at least onerhinitis symptom occurs within about 30 minutes of administration. Thehomeopathic dilution of capsicum may be at a concentration of about0.00060% to about 0.010% w/w or containing about 0.1 to about 2.0 ppmtotal capsaicinoids. The homeopathic dilution of capsicum may be at aconcentration of about 0.0020% to about 0.0080% w/w or containing about0.3 to about 1.5 ppm total capsaicinoids. The homeopathic dilution ofcapsicum may be at a concentration of about 0.0030% to about 0.0080% w/wor containing about 0.5 to about 1.5 ppm total capsaicinoids. Thecomposition may comprise rosemary extract at a concentration of about0.02% to about 0.25% w/w, at a concentration of about 0.05% to about0.10% w/w, or at a concentration of about 0.06% to about 0.07% w/w. Thefirst relief from at least one symptom may occur within about 30 minutesof administration, within about 15 minutes of administration, withinabout 5 minutes of administration, within about 3 minutes ofadministration, or within about 1 minute of administration. The rhinitissymptoms relieved may comprise at least one of nasal congestion, sinuspressure, sinus pain, headache, or a combination thereof. Thecomposition may comprise eucalyptol at a concentration of about 0.07% toabout 0.15% w/w, vegetable glycerin at a concentration of about 3.5% toabout 5.0% w/w, vegetable glycerin at a concentration of about 3.9% toabout 4.5% w/w, ascorbic acid at a concentration of about 0.10% to about0.90% w/w, sea salt at a concentration of about 0.40% to about 1.2% w/w,potassium sorbate at a concentration of about 0.05% to about 0.3%, or acombination thereof. It is surprising and unexpected that a homeopathicdose of capsicum, such as, but not limited to, 5% or less of therapeuticdoses known in the art, is still an effective dose. As such, it issurprising and unexpected that a homeopathic dose of capsicum wouldstill provide a significant benefit as shown in an embodiment of thepresent invention.

An embodiment of the present invention is a composition comprising anaqueous solution of capsicum at a concentration of about 0.00060% toabout 0.010% w/w, or containing about 0.1 to about 2.0 ppm totalcapsaicinoids, including, but not limited to, capsaicin, wherein thecomposition is suitable for intranasal administration to a human in needthereof, wherein the first relief from at least one rhinitis symptomoccurs within about 30 minutes of administration, and wherein thesymptoms may comprise at least one of nasal congestion, sinus pressure,sinus pain, headache or a combination thereof. In an embodiment theaqueous solution of capsicum comprises a homeopathic dilution ofcapsicum. In an embodiment the aqueous solution of capsicum comprises ahomeopathic dilution of Capsicum annum. In an embodiment, the aqueoussolution of capsicum may be at a concentration of about 0.0020% to about0.0080% w/w, or containing about 0.3 to about 1.5 ppm totalcapsaicinoids. In an embodiment the aqueous solution of capsicum may beat a concentration of about 0.0030% to about 0.0080% w/w, or containingabout 0.5 to about 1.5 ppm total capsaicinoids.

An embodiment of the present invention is a composition comprising anaqueous solution of capsicum at a concentration of about 0.00060% toabout 0.010% w/w, resulting in about 0.1 to about 2.0 ppm totalcapsaicinoids. An embodiment may also comprise rosemary extract at aconcentration of about 0.02% to about 0.25% w/w, or comprise rosemaryextract at a concentration of about 0.05% to about 0.10% w/w or about0.06% to about 0.07% w/w, wherein the composition is suitable forintranasal administration to a human in need thereof, wherein the firstrelief from at least one rhinitis symptom occurs within about 30 minutesof administration, and wherein the symptoms comprise at least one ofnasal congestion, sinus pressure, sinus pain, headache or a combinationthereof. In an embodiment the aqueous solution of capsicum may or maynot comprise a homeopathic dilution of capsicum. In an embodiment theaqueous solution of capsicum may be at a concentration of about 0.0020%to about 0.0080% w/w, or containing about 0.3 to about 1.5 ppm totalcapsaicinoids. In an embodiment the aqueous solution of capsicum may beat a concentration of about 0.0030% to about 0.0080% w/w, or containingabout 0.5 to about 1.5 ppm total capsaicinoids. It is surprising andunexpected that a homeopathic dose of capsaicin, such as, but notlimited to, 5% or less of therapeutic doses known in the art, is stillan effective dose. As such, it is surprising and unexpected that ahomeopathic dose of capsicum would still provide a significant benefitas shown in an embodiment of the present invention.

A surprising and unexpected result according to an embodiment of thepresent invention is that the presence of the rosemary extract acts toincrease the tolerability of the capsicum in the composition to theuser. Applicant is not aware of any disclosure, teaching, or suggestionin the related art that the presence of rosemary extract in acomposition containing capsicum would act to make the capsicum moretolerable to the user.

An embodiment of the present invention is a composition comprising anaqueous solution of capsicum at a concentration of about 0.00060% toabout 0.010% w/w. An embodiment may comprise eucalyptol at aconcentration of about 0.07% to about 0.15% w/w, wherein the compositionis suitable for intranasal administration to a human in need thereof,wherein the first relief from at least one symptom occurs within about30 minutes of administration, and wherein the symptoms consist of atleast one of nasal congestion, sinus pressure, sinus pain, headache or acombination thereof. In an embodiment the eucalyptol may be at aconcentration of about 0.13% w/w. In an embodiment the aqueous solutionof capsicum comprises a homeopathic dilution of capsicum. In anembodiment the aqueous solution of capsicum may comprise a homeopathicdilution of Capsicum annum. In one embodiment, the aqueous solution ofcapsicum may be at a concentration of about 0.0020% to about 0.0080%w/w, or containing about 0.3 to about 1.5 ppm total capsaicinoids. Inone embodiment, the aqueous solution of capsicum may be at aconcentration of about 0.0030% to about 0.0080% w/w, or containing about0.5 to about 1.5 ppm total capsaicinoids. In an embodiment thecomposition may also comprise rosemary extract at a concentration ofabout 0.02% to about 0.25% w/w, about 0.05% to about 0.10% w/w orcomprise rosemary extract at a concentration of about 0.06% to about0.07% w/w. In an embodiment the composition does not require theadministration of a separate agent before, during, and/or afteradministration of the composition to enable tolerance of thecomposition. In an embodiment the composition is self-administered bythe human in need thereof.

In an embodiment the composition may also comprise vegetable glycerin ata concentration of about 3.5% to about 5.0% w/w or at a concentration ofabout 3.9% to about 4.5% w/w. In an embodiment the composition maycomprise ascorbic acid at a concentration of about 0.10% to about 0.90%w/w, sea salt at a concentration of about 0.40% to about 1.2% w/w,potassium sorbate at a concentration of about 0.05% to about 0.3%, or acombination thereof. In an embodiment the composition may provide thefirst relief from at least one symptom within about 30 minutes, 15minutes, 5 minutes, 3 minutes, or within about 1 minute ofadministration.

An embodiment of the present invention is a composition comprising anaqueous solution of capsicum at a concentration of about 0.00060% toabout 0.010% w/w, or containing about 0.1 to about 2.0 ppm totalcapsaicinoids and rosemary extract at a concentration of about 0.02% toabout 0.25% w/w. An embodiment may further comprise eucalyptol at aconcentration of about 0.07% to about 0.15%, vegetable glycerin at aconcentration of about 3.5% to about 5.0% w/w or a combination thereof,wherein the composition is suitable for intranasal administration to ahuman in need thereof, wherein fast relief is first relief from at leastone symptom occurring within about 30, 15, or 5 minutes ofadministration, wherein the symptoms consist of at least one of nasalcongestion, sinus pressure, sinus pain, headache or a combinationthereof. The composition may also comprise ascorbic acid at aconcentration of about 0.10% to about 0.90% w/w, sea salt at aconcentration of about 0.40% to about 1.2% w/w and potassium sorbate ata concentration of about 0.05 to about 0.3%, or a combination thereof.The composition may provide first relief from at least one symptomwithin about 3 minutes of administration or may provide first relieffrom at least one symptom within about 1 minute of administration.

An embodiment of the present invention is an aqueous solution suitablefor intranasal administration to a human in need thereof, comprising anaqueous solution of capsicum at a concentration of about 0.00060% toabout 0.010% w/w, or containing about 0.1 to about 2.0 ppm totalcapsaicinoids, rosemary extract at a concentration of about 0.02% toabout 0.25% w/w, eucalyptol at a concentration of about 0.07% to about0.15%, vegetable glycerin at a concentration of about 3.5% to about 5.0%w/w, or a combination thereof, wherein, on introduction into the nasalcavity of a human in need thereof, first relief from at least onesymptom occurs within about 30, 15, or 5 minutes of administration,wherein symptoms comprise at least one of nasal congestion, sinuspressure, sinus pain, headache or a combination thereof. In anembodiment the aqueous solution of capsicum comprises a homeopathicdilution of capsicum. In an embodiment the aqueous solution of capsicummay be at a concentration of about 0.0020% to about 0.0080% w/w, orcontaining about 0.3 to about 1.5 ppm total capsaicinoids.

An embodiment of the present invention is a method for treating a humanin need thereof comprising the steps of intranasal administration of anaqueous solution of capsicum and effecting the relief of at least onerhinitis symptom. The aqueous solution of capsicum may comprise ahomeopathic dilution of capsicum, including, but not limited to,Capsicum annum. In an embodiment, the composition may comprise about0.00060% to about 0.010% w/w capsicum, or containing about 0.1 to about2.0 ppm total capsaicinoids, effecting the first relief from symptoms ofat least one of nasal congestion, sinus pressure, sinus pain, headacheor a combination thereof within about 30, 15, or 5 minutes ofadministration. In an embodiment the capsicum may be present in solutionat a concentration of about 0.0020% to about 0.0080% w/w, or containingabout 0.3 to about 1.5 ppm total capsaicinoids. In an embodiment thefirst relief from at least one symptom may occur within about 3 minutesor within about 1 minute of administration.

An embodiment of the present invention is a method for treating a humanin need thereof comprising the steps of intranasal administration of anaqueous solution of capsicum comprising about 0.00060% to about 0.010%w/w capsicum, or containing about 0.1 to about 2.0 ppm totalcapsaicinoids, and rosemary extract at a concentration of about 0.02% toabout 0.25% w/w, effecting the first relief from symptoms of at leastone of nasal congestion, sinus pressure, sinus pain, headache or acombination thereof within about 30, 15, or 5 minutes of administration.In an embodiment the aqueous solution of capsicum may comprise ahomeopathic dilution of capsicum, and may comprise a homeopathicdilution of Capsicum annum. In an embodiment the capsicum may be presentin solution at a concentration of about 0.0020% to about 0.0080% w/w, orcontaining about 0.3 to about 1.5 ppm total capsaicinoids. In anembodiment the first relief from at least one symptom may occur withinabout 3 minutes of administration or within about 1 minute ofadministration.

An embodiment of the present invention is a method for treating a humanin need thereof comprising the steps of intranasal administration of anaqueous solution of capsicum comprising about 0.00060% to about 0.010%w/w capsicum, or containing about 0.1 to about 2.0 ppm totalcapsaicinoids, and eucalyptol at a concentration of about 0.07% to about0.15% w/w, effecting the first relief from symptoms of at least one ofnasal congestion, sinus pressure, sinus pain, headache or a combinationthereof within about 30, 15, or 5 minutes of administration. In anembodiment the aqueous solution of capsicum comprises a homeopathicdilution of capsicum. In an embodiment the capsicum may be present insolution at a concentration of about 0.0020% to about 0.0080% w/w, orcontaining about 0.3 to about 1.5 ppm total capsaicinoids. In anembodiment the first relief from at least one rhinitis symptom may occurwithin about 3 minutes of administration.

An advantage of an embodiment of the present invention is anintranasally administered composition having a quick and/or fast onsetof action with an average time to first relief of at least one symptomof less than about thirty minutes, about fifteen minutes, about fiveminutes, about three minutes, and even less than about one minute.

An embodiment of the present invention is an intranasally administeredcomposition that provides relief from at least one of nasal congestion,sinus pressure, sinus pain and headache with an improved therapeuticresponse that continues over time with at least one of nasal congestion,sinus pressure, sinus pain and headache significantly improved at about5, 10, 15, 30 and/or 60 minutes. An advantage of an embodiment of thepresent invention is an intranasally administered composition having arapid onset of action and significant reduction of symptoms that may bean attractive mono-therapy or adjunctive therapy for the management ofrhinitis symptoms.

An embodiment of the present invention is an intranasal compositionwherein users experience little to no rebound congestion. An advantageof an embodiment of the present invention is an intranasal compositionwherein users experience essentially no alteration, or even animprovement, in olfaction versus placebo after continued use. Anadvantage of an embodiment of the present invention is a nasallyadministered composition that provides a rapid onset of relief forrhinitis subjects, while also providing safe, sustained relief over thecourse of a treatment period.

An advantage of an embodiment of the present invention is anintranasally administered composition wherein during a treatment periodis significantly effective at improving at least one of nasalcongestion, sinus pressure, sinus pain and headache compared to placebo.

An advantage of an embodiment of the present invention is anintranasally administered composition that is well-tolerated and withprolonged treatment results in substantially no reduction in olfaction.

An advantage of an embodiment of the present invention is an agent thatmay be used as a mono-therapy comprising capsaicin, dihydrocapsaicin,and nordihydrocapsaicin and other capsaicinoids.

In an embodiment of the present invention, the agent comprises betweenabout 0.000001% to about 0.01% by weight of the total water orsuspension material weight of capsicum comprising at least, but notlimited to, capsaicin, dihydrocapsaicin, and nordihydrocapsaicin,resulting in about 0.0001 to about 1.5 ppm total capsaicinoids.

In another embodiment of the present invention the agent comprisesbetween about 0.1 ppm to about 2.0 ppm total capsaicinoids comprising atleast, but not limited to, capsaicin, dihydrocapsaicin, andnordihydrocapsaicin.

In another embodiment of the present invention, the agent comprisescapsicum, comprising capsaicin, dihydrocapsaicin, andnordihydrocapsaicin, having a heat range of about 100,000 to about1,000,000 Scoville Heat Units.

These and other embodiments of the present invention are more fullydescribed in connection with the detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a diagram of the mean fluorescent intensity.

FIG. 2 is a diagram of a schedule of the study protocol.

FIG. 3 is a diagram of the magnitude of improvement for TNSS.

FIG. 4 is a diagram of symptom scores of ICX72 and a placebo.

DETAILED DESCRIPTION OF THE INVENTION

Capsicum is derived from several Capsicum pepper varieties. The Capsicumvariety utilized in embodiments of the present invention is derived fromcayenne pepper plants, which may comprise at least one of Capsicumbaccatum, Capsicum annum, and Capsicum frutescens, or a combinationthereof. The capsicum comprises capsaicin, dihydrocapsaicin, andnordihydrocapsaicin and possibly other capsaicinoids as activeingredients. The capsicum utilized in an embodiment of the presentinvention may comprise an all natural, water soluble and/or solubleliquid suspension material. The aqueous solution of capsicum maycomprise a homeopathic dilution of capsicum. The aqueous solution ofcapsicum may comprise a homeopathic dilution of Capsicum annum. The useof capsicum comprising capsaicin, dihydrocapsaicin, nordihydrocapsaicin,and possibly other capsaicinoids as opposed to synthetic capsaicin mayallow for repeated use and effective delivery without causing anuncomfortable and/or intolerable burning sensation in the nasal mucosaof the user. However, it is within the scope of the present inventionthat a combination of at least one synthetic capsaicinoid could also beused.

Embodiments of the present invention relate to an agent comprisingcapsicum comprising capsaicin, dihydrocapsaicin, nordihydrocapsaicin,and other capsaicinoids to relieve at least one rhinitis symptom in ahuman in need thereof. The aqueous solution of capsicum may comprise ahomeopathic dilution of capsicum.

In an embodiment of the present invention, the composition may comprisebetween about 0.000001% to about 0.008% by weight of the total water orsuspension material weight of capsicum comprising capsaicin,dihydrocapsaicin, and nordihydrocapsaicin among others, resulting inabout 0.0001 to about 1.5 ppm total capsaicinoids.

In an embodiment of the present invention the composition comprisesbetween about 0.1 to about 2.0 ppm total capsaicinoids present incapsicum, including, but not limited to, capsaicin, dihydrocapsaicin,and nordihydrocapsaicin.

In an embodiment of the present invention the composition may comprisecapsicum including capsaicin, dihydrocapsaicin, and nordihydrocapsaicinand possibly other capsaicinoids having a heat range of between about100,000 to about 1,000,000 Scoville Heat Units. The capsicum including,but not limited to, capsaicin, dihydrocapsaicin, and nordihydrocapsaicinis present in a non-caustic and safe amount.

In an embodiment the aqueous solution of capsicum comprises ahomeopathic dilution of capsicum. In an embodiment the aqueous solutionof capsicum comprises a homeopathic dilution of Capsicum annum.

An embodiment of the present invention comprises rosemary extract at aconcentration of about 0.02% to about 0.50% w/w in addition to thecapsicum. The composition may comprise rosemary extract at aconcentration of about 0.05% to about 0.10% w/w, or at a concentrationof about 0.06% to about 0.07% w/w.

A surprising and unexpected result according to an embodiment of thepresent invention is that the presence of the rosemary extract acts toincrease the tolerability of the capsicum in the composition to theuser.

Applicant is not aware of any disclosure, teaching, or suggestion in theart that the addition of rosemary extract in a composition containingcapsicum would act to make the capsicum more tolerable to the user.

An embodiment of the present invention may comprise eucalyptol at aconcentration of about 0.07% to about 0.15% w/w in addition to thecapsicum.

An embodiment of the present invention may comprise at least one ofvegetable glycerin at a concentration of about 3.5% to about 5.0% w/w,vegetable glycerin at a concentration of about 3.9% to about 4.5% w/w,ascorbic acid at a concentration of about 0.10% to about 0.90% w/w, seasalt at a concentration of about 0.40% to about 1.2% w/w, potassiumsorbate at a concentration of about 0.05% to about 0.30% or acombination thereof, in addition to the capsicum.

In an embodiment of the present invention the composition may be anintranasal spray. In a further embodiment of the present invention, thecomposition may be an intranasal spray wherein the capsicum is releasedin a metered dose. In yet another embodiment of the present inventionthe composition may be an intranasal spray wherein the capsicum isreleased in a time released dose. In yet another embodiment of thepresent invention the composition may be disposed in, about and/oraround a swab for intranasal delivery.

An embodiment of the invention relates to a method of treating a humanin need thereof, by delivering the composition described herein andwherein capsicum including, but not limited to, capsaicin,dihydrocapsaicin, and nordihydrocapsaicin is the effective agent. Themethod comprises the intranasal administration of capsicum comprising,but not limited to, capsaicin, dihydrocapsaicin, and nordihydrocapsaicineffecting the relief of at least one rhinitis symptom. It will beapparent to one skilled in the art that the following are examples offormulations and many more formulations are possible and fall withinembodiments of the present invention as disclosed and claimed herein.

Example 1

It is hypothesized that capsicum, comprising capsaicinoids, includingcapsaicin, and possibly other ingredients in Applicant's composition,used for relief of rhinitis and allergic symptoms act via activation ofTRP-family receptors. Applicant has developed an in vitro fluorometricassay to measure receptor activity in the presence of variousconcentrations of capsaicin/capsaicinoids. The activation of thereceptors in the in vitro assay correlates with Applicant's demonstratedsymptom relief as evidenced in the examples below. Specifically, thegoal of the in vitro assay is to quantitatively measure TRPV activationto determine the dose response of airway component cells to Applicant'scompositions comprising capsaicin/capsaicinoids. To this end, Applicantdeveloped a new assay for transient receptor protein vanilloid (“TRPV”)activation in cells. The assay is fluorometric in nature, relying upon acalcium-binding fluor, Fura-4. (available from Invitrogen Life Sciencesand other vendors). Fura-4 fluoresces at a specific wavelength when itbinds to calcium. Cells are loaded with Fura-4, and under digitalconfocal observation exposed to capsaicin/capsaicinoid containingcompositions. The signal intensity over single cells is captured for0.5-5 minutes and the result expressed as normalized (to baseline)signal intensity over time.

As shown in FIG. 1, the activation of a calcium channel by thecomposition will result in an increase in fluorescence. In the case ofTRPV channels, since the channels are activated transiently (hence thename, Transient Receptor Potential V channels, TRPV), the signalsrapidly diminish in 1-2 minutes. The effects of thecapsaicin/capsaicinoid-containing compositions to TRPV1 knockout cells(gene targeted ablation of the TRPV1, capsaicin receptor) is shown.Applicant performed the assay using compositions comprising varyinglevels of capsaicin/capsaicinoids, shown in FIG. 1, and achieved adose-response, demonstrating that the in vitro assay distinguishesresponses of about 1 ppm (n=14), 0.5 ppm (n=12), 0.25 ppm (n=8) and 0.10ppm (n=4) concentration of total capsaicinoids, including capsaicin. Theconcentration at 1 ppm is about 0.0064% w/w capsicum, 0.5 ppmconcentration is about 0.0032% w/w capsicum, 0.25 ppm concentration isabout 0.0016% w/w capsicum, and the 0.10 ppm concentration is about0.0008% capsicum. Responses are statistically different at the peak ofactivation (P<0.05). Mean (curves) and standard deviation (verticallines) of fluorescent intensities of cells treated with the indicatedcompositions are shown. Formulations were perfused at time=0, andintensity plotted vs. time (seconds). Each signal was normalized to thebaseline reading of that cell or part of a cell before infusion (toaccount for differential loading of Fura-4 and baseline differences inintracellular calcium levels). Applicant is not aware of any known invitro studies that show the receptor response resulting from theadministration of homeopathic doses of capsicum/capsaicinoid containingcompositions.

In addition to the dose-response, the assay demonstrates that there isno calcium uptake in the blank sample (no aromatics, no capsaicinoids,n=1, Preliminary Data). Cells with gene targeted ablation of the TRPV1channel (“TRPV1 KO”) also show no increase in signal (n=1, PreliminaryData), supporting that the signal activated by thecapsaicin/capsaicinoid containing formulations is indeedTRPV1-dependent. Applicant concludes from the data that the capsaicinresponse is primarily due to TRPV1, but expects that other TRPs willrespond to the aromatics and the affect may be different in differentcell types.

The results of this study indicate that a range of capsaicinoids fromabout 0.1 ppm to about 1 ppm total capsaicinoids significantly activatesthe TRPV channels over the controls. Applicant may easily extrapolatethis data to reasonably infer and support a concentration range ofcapsaicin/capsaicinoids that will be effective at relieving rhinitissymptoms in humans in need thereof. Various formulations andconcentrations of capsaicin/capsaicinoids have been used by Applicant tosuccessfully treat these symptoms as shown in Examples 2-5 below. Thefollowing examples of formulations of compositions wherein the totalcapsaicinoids provide quick, effective relief from symptoms.

Example 2

A clinical study was performed to assess the efficacy and safety of anewly formulated intranasally administered capsicum composition (“ICX”)used continuously over a two week treatment period in chronic rhinitissubjects who have a significant component of NAR. The ICX formulationcomprises from about 0.00060% to about 0.010% w/w, or comprising about0.1 to about 2.0 ppm total capsaicinoids, about 0.0020% to about 0.0080%w/w, resulting in about 0.3 to about 1.5 ppm total capsaicinoids, orpreferably about 0.0030% to about 0.0080% w/w, resulting in about 0.5 toabout 1.5 ppm total capsaicinoids. The ICX formulation further comprisesrosemary extract at a concentration of about 0.02% to about 0.25% w/w,eucalyptol at a concentration of about 0.07 to about 0.15%, vegetableglycerin at a concentration of about 3.5% to about 5.0% w/w, ascorbicacid at a concentration of about 0.10% to about 0.90% w/w and sea saltat a concentration of about 0.40% to about 1.2% w/w. One embodiment mayalso comprise potassium sorbate at a concentration of about 0.05% toabout 0.30%. One embodiment of the ICX formulation comprises about0.0064% w/w capsicum, about 0.11% w/w eucalyptol, about 0.067% w/wrosemary extract, about 0.4 to about 0.7% w/w each ascorbic acid and seasalt, about 4.4% w/w vegetable glycerin, in purified water.

Forty-two informed, consented patients with a significant component ofNAR were randomized to receive either ICX (n=20) or a filtered watercontrol (n=22), as shown in FIG. 4, administered 1-2 puffs in eachnostril twice daily over 2 weeks. The primary endpoint was change intotal nasal symptom scores (“TNSS”) from baseline to end of study.Secondary endpoints included changes in individual symptom scores (nasalcongestion, sinus pain, sinus pressure, headache, sneezing, rhinorrhea,and post-nasal drainage) over two weeks and average time to firstrelief. Mean TNSS and individual symptom scores were also recorded aftersingle dosing with ICX vs. placebo at 5, 10, 15, 30 and 60 minuteintervals. Rhinitis quality-of-life domains at end of study, and use ofrescue medication and safety endpoints were also analyzed. All data wasanalyzed by the Statistical Analysis System (“SAS”).

Statistically significant differences in changes from baseline to end ofstudy between the ICX and placebo groups were observed for TNSS and eachindividual symptom (p<0.01). The average time to first relief for ICXsubjects was 52.6 seconds which was significantly less than placebo(p<0.01). For ICX subjects, nasal congestion, sinus pain, sinus pressureand headache were significantly improved at 5, 10, 15, 30, whichpersisted up until 60 minutes for nasal congestion and sinus pain(p<0.05). No significant difference between groups in adverse events orrescue medication was observed. ICX subjects experienced no reboundcongestion and demonstrated an improvement in olfaction versus placeboat the end of study visit.

This is the first controlled clinical trial to demonstrate that the ICXcomposition comprising capsicum provides a rapid onset of relief forrhinitis subjects, while also providing safe, sustained relief over thecourse of the two week treatment period.

This was a randomized, placebo controlled, double-blind parallel studyincluding patients previously diagnosed with non-allergic rhinitis(“NAR”) or “mixed rhinitis” defined as allergic rhinitis (“AR”) withsignificant NAR triggers. (Bernstein J A. Characteristics ofNon-Allergic Rhintiis. World Allergy Journal 2009; 2:102-5. Bernstein JA, Rezvani, M. Mixed Rhinitis: A New Subclass of Chronic Rhinitis. In:Kaliner M, ed. Current Review of Rhinitis, 2nd ed 2006; Philadelphia,Pa.: 69-78

Forty-two patients between the ages of 18-60 were enrolled in thisstudy. All subjects signed an informed consent approved by a central IRBprior to enrollment. Subjects were required to have a diagnosis of NARwith or without an allergic component (i.e. mixed rhinitis) for at leastsix months prior to enrollment. Mixed rhinitis was defined as being skinprick test positive, defined as a wheal ≧3 mm in diameter than salinecontrol with surrounding erythema, to one or more aeroallergens inaddition to having significant symptoms induced by chemical irritants,strong odors, weather or temperature changes. (Bernstein J A, Rezvani,M. Mixed Rhinitis: A New Subclass of Chronic Rhinitis. In: Kaliner M,ed. Current Review of Rhinitis, 2nd ed 2006; Philadelphia, Pa.: 69-78.)The magnitude of each subject's non-allergic rhinitis component wasconfirmed using a gender specific irritant index score previouslydemonstrated to correlate with a diagnosis of NAR or MR. (Bernstein J A.Characteristics of Non-Allergic Rhintiis. World Allergy Journal 2009;2:102-5.) Twenty subjects received ICX and 22 received placebo control(filtered water). Thirty-three of the 42 participants had a diagnosis ofMR, and 9 had an NAR diagnosis. These diagnoses were evenly distributedbetween the ICX and placebo groups. All subjects enrolled into thisstudy and randomized to ICX or placebo control and who received at leastone dose of study drug were included in this intent-to-treat analysis.

All subjects were required to have previously experienced symptomaticrelief while using their currently prescribed rhinitis medications andwere required to exhibit moderate to severe rhinitis symptoms while offthese medications at the time of randomization. Symptom severity wasdefined as a morning or evening nasal congestion and/or post nasaldrainage score of at least 5 out of 10 on three separate symptomassessments during the 7 day pre-randomization medication wash-outperiod. This included being symptomatic at least 24 hours prior to andincluding the day of randomization. Subjects were required to complywith all study related visits and procedures and had to be in generallygood health without any uncontrolled chronic health problems.

Subjects were excluded if they had an acute sinus infection in the past30 days, had a history of nasal polyps or other nasal structuralproblems, were treated with oral corticosteroids in the past 7 days,were active smokers or had passive smoke exposure at least six monthsprior to enrollment. Finally, pregnant women were not permitted toparticipate and women of child bearing age were required to useacceptable birth control throughout the study.

There were a total of three study visits and one interim phone call, asshown in FIG. 2.

During visit one, subjects who signed an informed consent and met allinclusion/exclusion criteria (except for symptom scores), were removedfrom all rhinitis medications for 7 days to determine if they wouldfulfill the symptom entry criteria. They were permitted to usediphenhydramine 25 mg up to 200 mg/day as rescue medication throughoutthe study. During visit two, subjects who fulfilled allinclusion/exclusion criteria including the symptom score criteria, wererandomized to receive either ICX or filtered water placebo, 1-2 puffseach nostril, twice daily. During visit 2, subjects were given theirfirst dose of study drug or placebo in the office. Using the stopwatchmethod, subjects clicked the stopwatch when they felt the first onset ofsymptom relief. (Black P, Max M B, Desjardins P, Norwood T, Ardia A,Pallotta T. A randomized, double-blind, placebo-controlled comparison ofthe analgesic efficacy, onset of action, and tolerability of ibuprofenarginate and ibuprofen in postoperative dental pain. Clin Ther 2002;24:1072-89.) They were then immediately instructed to complete a symptomscore card. Subjects also completed symptom score cards at 5, 10, 15, 30and 60 minute intervals during this visit.

An interim phone call to the subject's home was made 7 days later toconfirm compliance with completing home symptom diaries and to assessfor adverse events and rescue medication requirements. The study endedat visit three, two weeks after randomization (visit 2).

During each visit, all subjects had a directed medical history, nasalexamination, and a review of concomitant and/or rescue medications.During visits 1 and 3, all subjects underwent acoustic rhinometry andautomated olfactometry to assess nasal congestion and smell,respectively. (Bernstein J A, Bernstein I L. A novel case ofmealworm-induced occupational rhinitis in a school teacher. AllergyAsthma Proc 2002; 23:41-4. Rezvani M, Brandt D, Bernstein J A, HastingsL, Willwerth J. Investigation of olfactory threshold responses inchronic rhinitis subtypes. Ann Allergy Asthma Immunol 2007; 99:571-2.)Pregnancy tests were performed on all women of child bearing age atvisits 1 (screening) and 2 (randomization). Rescue medication andadverse events were assessed at visit 2, during the interim phone call,and at visit 3.

Symptom scores and rescue medication requirements, consisting ofdiphenhydramine 25-50 mg up to four times a day (maximum dose 200mg/day), were recorded on subject's home diaries over the three weekstudy period.

The primary endpoint was the change in the 12 hour reflective total TNSSrecorded by the patient each evening in a daily diary, from baseline tothe end of the study (2 weeks). TNSS was a composite score that includednasal congestion, post-nasal drainage, sneezing, rhinorrhea, sinus pain,sinus pressure and headache. These symptoms were chosen based on the“Allergies in America survey” which cited these as the worst symptomsand/or co-morbid conditions experienced by chronic rhinitis patients.(Blaiss M S, Meltzer E O, Derebery M J, Boyle J M. Patient andhealthcare-provider perspectives on the burden of allergic rhinitis.Allergy Asthma Proc 2007; 28 Suppl 1:S4-10.) Each symptom was rated on a10 point Likert scale and therefore, the highest possible TNSS was 70,where a higher score reflects more intense symptoms.

Secondary endpoints included changes in 12 hour reflective symptomscores of nasal congestion, post-nasal drainage, sneezing, rhinorrhea,sinus pain, sinus pressure and headache recorded at home daily bypatients on diary cards over a 2-week period and the time to firstrelief of symptoms recorded in the physician office at visit 2, aftersingle dosing with ICX or placebo.

Other endpoints included changes in symptom scores (TNSS, nasalcongestion, post-nasal drainage, sneezing, rhinorrhea, sinus pain, sinuspressure and headache) at the time to first relief and assessment ofrescue medication requirements during the entire 2 week study period.

Adverse events, olfaction as measured using an automated olfactometer(Osmic Enterprises, LLC) (Rezvani M, Brandt D, Bernstein J A, HastingsL, Willwerth J. Investigation of olfactory threshold responses inchronic rhinitis subtypes. Ann Allergy Asthma Immunol 2007; 99:571-2),and nasal congestion using an acoustic rhinometer (Ecco Vision, HoodInstruments, Pembroke, Mass.) to assess for increased nasal resistance(i.e., a rebound effect) (Bernstein J A, Bernstein I L. A novel case ofmealworm-induced occupational rhinitis in a school teacher. AllergyAsthma Proc 2002; 23:41-4) were recorded and assessed prior torandomization while off all rhinitis medications and at the end ofstudy.

The sample sizes for the ICX drug and placebo control groups were chosenbased on feasibility and other intranasal capsaicin studies thatreported clinically meaningful results. (Blom H M, Van Rijswijk J B,Garrelds I M, Mulder P G, Timmermans T, Gerth van Wijk R. Intranasalcapsaicin is efficacious in non-allergic, non-infectious perennialrhinitis. A placebo-controlled study. Clin Exp Allergy 1997;27:796-801.) For sample sizes of 20 per group, the power was 80% todetect a difference of 2 units in TNSS mean scores from baseline to 14days between the drug and placebo groups assuming a 2-tailed alpha=0.05.The effect size (ratio of mean difference to TNSS standard deviation)was equal to 0.8.

For all analyses a p-value <0.05 was used to judge statisticalsignificance unless stated otherwise. The analyses were performed usingSAS for Windows, version 9.2, SAS Institute, Cary N.C.

Subject demographics: The demographic characteristics of the subjectpopulation are summarized in Table 1.

TABLE 1 Demographic Characteristics of Study Participants CapsaicinPlacebo All (N = 20) (N = 22) (N = 42) AGE, mean 46.9 (36, 59) 45.2 (29,58) 46.0 (29, 59) (min, max) RACE, N (%) Caucasian 17 (85%) 17 (77%) 34(81%) African American 2 (10%) 5 (23%) 7 (17%) Other 1 (5%) 0 (0%) 1(2%) GENDER, N (%) Male 4 (20%) 3 (14%) 7 (17%) Female 16 (80%) 19 (86%)35 (83%) Note: No significant differences were seen between the ICX72and placebo groups (p > .05).There were no significant differences between subjects in the ICX andplacebo groups with respect to age, race and gender.

Mean Changes in TNSS and Individual Symptom Scores from Baseline to Endof Study for ICX and Placebo Groups: Mean baseline symptom scores of theICX and placebo groups were not significantly different as shown inTable 2.

TABLE 2 Mean Change from Baseline to End of Study (Standard Error) ofTNSS and Individual Symptom Scores for ICX72 and Placebo Groups ICX72 (N= 20) Placebo (N = 22) Change: Change: Baseline- % Rel Baseline- % RelSymptom Baseline End Change Baseline End Change TNSS* 23.7 (2.2)  12.4(1.1)  52% 26.0 (2.2)  7.7 (1.2) 30% Nasal Congestion 5.1 (0.5) 2.7(0.3) 53% 5.3 (0.4) 1.4 (0.3) 27% Sinus Pressure 5.4 (0.5) 3.3 (0.3) 62%3.7 (0.4) 1.5 (0.3) 29% Sinus Pain 4.5 (0.5) 2.8 (0.3) 64% 4.8 (0.5) 1.6(0.3) 33% Headache 4.9 (0.5) 3.2 (0.4) 65% 4.8 (0.5) 1.8 (0.3) 37%Sneezing 1.6 (0.4) 0.9 (0.2) 53% 2.4 (0.4) 0.8 (0.2) 19% Rhinorrhea 2.6(0.5) 0.5 (0.3) 19% 2.6 (0.4) 0.6 (0.3) 24% PND 4.7 (0.5) 2.2 (0.4) 47%5.6 (0.5) 1.7 (0.3) 30% Note: For each variable, baseline differencesbetween groups were not statistically different (p > 0.05). Percentrelative change of each symptom was larger for ICX72, compared withplacebo, except rhinorrhea. Mean changes from baseline to end of studywere significantly different between ICX72 and placebo for TNSS, nasalcongestion, sinus pressure, sinus pain and headache (p < 0.006 for eachvariable determined by Bonferroni adjustment, overall p-value = 0.05).

The mean differences between the ICX and placebo groups with respect tochanges in TNSS, nasal congestion, sinus pressure, sinus pain andheadache from baseline to end of study were statistically greater forICX compared to placebo (p<0.01). FIG. 3 illustrates the magnitude ofthis effect for TNSS and the individual symptoms that significantlyimproved. No significant differences between groups in changes frombaseline to end of study were observed for sneezing, post-nasal drip andrhinorrhea (p>0.05).

Times to first relief: The average time to first relief for ICX wasequal to 52.6 seconds (0.8 min), which was significantly lower than theaverage time of first relief for placebo subjects (p<0.01). Eightypercent of subjects receiving ICX experienced first relief in less thanone minute compared to 45% of subjects receiving placebo (p<0.05).Symptoms that significantly improved at time to first relief were nasalcongestion, sinus pressure and headache (p<0.05) as shown in Table 3.

TABLE 3 Mean Change from Baseline to First Relief (Standard Error) ofTNSS and Individual Symptom Scores for ICX72 and Placebo Groups ICX72 (N= 20) Placebo (N = 22) ^(a) Change: Change: Baseline- Baseline- First %Rel First % Rel Symptom Baseline Relief Change Baseline Relief ChangeTNSS 23.7 (2.2)  3.4 (1.5) 14% 26.0 (2.2)  2.3 (7.7)   9% NasalCongestion 5.1 (0.5) 1.3 (0.4) 25% 5.3 (0.4)   0 (2.2)   0% SinusPressure 5.4 (0.5) 1.7 (0.5) 32% 3.7 (0.4) −0.1(1.9)  −1% Sinus Pain 4.5(0.5) 1.2 (0.6) 27% 4.8 (0.5) −0.2(2.7)  −5% Headache 4.9 (0.5) 2.2(0.6) 44% 4.8 (0.5) −0.1(2.0)  −2% Sneezing 1.6 (0.4) 1.2 (0.3) 75.0%  2.4 (0.4) 0.5 (1.8)  19% Rhinorrhea 2.6 (0.5) −2.3(0.6)  −89%   2.6(0.4) −1.9(4.3)  −74%  PND 4.7 (0.5) 0.4 (0.7)  7% 5.6 (0.5) −0.6(5.4) −10%  ^(a) N = 22 placebo patients at baseline = 22. Four patients hadmissing data at first relief for each symptom. When a symptom at firstrelief was missing, less relief was assumed than was determined from allreported symptom changes at first relief, after adjusting for baseline.The minimum values at first relief of missing data weresymptom-specific. Mean symptom changes in the placebo group wereobtained from Tobit analysis, which accounts for the upward bias ofchanges calculated from observed data only. The probability ofunreported symptoms reflecting less relief than the minimum relief ofall other patients was combined with the probabilities of the observedsymptom values at first relief, to estimate mean changes at first reliefof each symptom for the placebo group. Note: For each variable, baselinedifferences between groups were not statistically different (p > 0.05).Mean changes from baseline to first relief were significantly differentbetween ICX72 and placebo for sinus pressure and headache only (p <0.006 for each variable determined by Bonferroni adjustment, overallp-value = 0.05).

Improvement in TNSS and Symptoms Scores for Intranasal CapsaicinCompared to Placebo At Fixed Time Periods: This analysis requiredsubjects to complete symptom score questionnaires at fixed time periodsbeginning at 5 minutes up to 60 minutes after the first dose.Differences were statistically significant for nasal congestion, sinuspressure, sinus pain and headache at 5, 10, 15 and 30 minutes whichpersisted for nasal congestion, sinus pressure and sinus pain up to 60minutes (p<0.05).

Rescue medications: Fewer subjects in the ICX group (n=6; 30% ofsubjects) compared to the placebo group (n=10; 45% of subjects),reported rescue medication usage during the first week afterrandomization.

Similarly, fewer subjects in the ICX group (n=4; 20% of subjects) versusthe placebo group (n=10; 45%) reported use of rescue medications duringthe second week after randomization.

Safety Analyses:

Olfactometry: The olfactory threshold means of ICX and placebo subjectsat baseline and end of study are summarized in Table 4.

TABLE 4 Mean Change from Baseline to End of Study (Standard Error) ofOlfactory Thresholds for ICX72 and Placebo Groups. ICX72 (N = 14)Placebo (N = 17) Change: Change: Baseline Baseline-End BaselineBaseline-End Olfactory 6.7 (0.4) −1.0 (0.6) 6.1 (0.6) +0.1 (0.5)Threshold N = number of patients A negative change (higher value at endof study) indicates improved olfaction. Baseline (defined as datacollected during visit 2 pre-drug) differences between groups were notsignificantly different (p > .05). Mean changes from baseline to end ofstudy were not significantly different between ICX72 and placebo groups(p > .05). End of study means were significantly different between ICX72(7.7) and placebo (6.0) (p < .05).There were no significant differences between baseline or the changefrom baseline to end of study olfactory threshold means for ICX andplacebo subjects (p>0.05). However, ICX subjects, had significantlyhigher olfactory threshold means compared to placebo at visit 3 (p<0.05)indicating that their sense of smell was actually improved during theend of study visit compared to placebo.

Acoustic Rhinometry: There was no significant difference in nasal meancross sectional areas or volumes at baseline (when subjects were removedfrom rhinitis medications) compared to end of study between ICX andplacebo subjects (data not shown). This indicates that increased nasalresistance, which is what would be seen with rebound nasal congestion,was not a side effect when ICX was used continuously over 2 weeks.

Adverse Events: There was no significant difference between ICX andplacebo in reported adverse events. Reported adverse events includedincreased nasal congestion, headaches, post-nasal drainage, rhinorrhea,transient stinging/burning, blood tinged mucus and fatigue. Ten percentof subjects on ICX and 27% on placebo, respectively (p=0.24) reportedadverse events during the first week after randomization whereas, 45% ofsubjects on ICX and 32% on placebo (p=0.53) reported adverse eventsduring the second week after randomization.

The results of this study clearly demonstrate that continuous treatmentwith ICX over a two week period was significantly effective at improvingTNSS, nasal congestion, sinus pressure, sinus pain and headache comparedto placebo. Furthermore, ICX has a quick onset of action as the averagetime to first relief was less than one minute (52.6 seconds). This rapidimprovement was most pronounced for nasal congestion, sinus pressure andsinus pain.

Interestingly, this improved therapeutic response continued over time asnasal congestion, sinus pressure, sinus pain and headache weresignificantly improved for ICX versus placebo at 5, 10, 15 and 30minutes and persisted for nasal congestion and sinus pain up until 60minutes. Thus, the rapid onset of action resulting in significantreduction of symptoms makes ICX an attractive mono-therapy or adjunctivetherapy for the management of chronic rhinitis symptoms.

Prolonged treatment with ICX resulted in no alteration in olfaction andin fact appeared to improve olfaction in patients receiving ICX versusplacebo at end of study. Furthermore, subjects receiving ICXcontinuously over two weeks showed no rebound congestion as reflected byimproved symptom scores and no change in nasal cross sectional areameasured by acoustic rhinometry. Other than a transient stingingsensation, ICX was well tolerated.

Several important points regarding this study should be emphasized.First, this is the first study to demonstrate that continuous dailytreatment with a composition comprising a lower concentration ofintranasal capsicum (ICX) over a two week period is safe and effectiveat improving chronic rhinitis symptoms. Second, in that all subjects inthis trial were required to have a significant component of NAR as partof their enrollment criteria, the beneficial effect of ICX supports animportant mechanistic role for TRP ion channels, specifically TRPV1 inNAR.

The robust effect of ICX on improving rhinitis symptoms and headachessuggest overlapping neurogenic mechanistic pathways for MR, NAR andheadaches, perhaps in part involving TRP ion channels, that requirefurther investigation. (Rapoport A M, Bigal M E, Tepper S J, Sheftell FD. Intranasal medications for the treatment of migraine and clusterheadache. CNS Drugs 2004; 18:671-85.)

There are several potential limitations of this study that warrantdiscussion. First, similar to what has been encountered for otherintranasal medications (Banov C H, Lieberman P. Efficacy of azelastinenasal spray in the treatment of vasomotor (perennial nonallergic)rhinitis. Ann Allergy Asthma Immunol 2001; 86:28-35), it was notpossible to formulate a placebo that caused mild transient stingingsimilar to the ICX formulation used in this trial. However, in order toensure that the study remained blinded to the subject, both the clinicalresearch coordinator and investigator used common written instructionsto direct the patient through different procedures thereby limiting anyunnecessary conversations during the study visits that could bias thesubject or coordinator. Second, it is worth noting that subjectsreceiving placebo in some instances experienced modest improvement inTNSS and specific symptom scores compared to baseline. The therapeuticeffect of placebo in clinical trials has been well established. (SpectorS L. The placebo effect is nothing to sneeze at. J Allergy Clin Immunol1992; 90:1042-3.) However, the finding that ICX had a faster onset ofaction and greater overall improvement in nasal congestion and TNSScompared to a placebo control at various time points throughout thestudy is a testimonial to its robust therapeutic benefits.

In summary, this is the first controlled clinical trial to demonstratethat ICX provides a rapid onset of relief for rhinitis subjects with anon-allergic component, while also providing safe, sustained relief overthe course of the two week treatment period.

Example 3

One example of the present invention relates to a headache reliefcomposition. The headache relief composition provides relief of symptomssuch as migraines, general headaches, tension, chronic and occasionalheadaches, and dizziness, and visual distortions associated withheadaches. The headache relief composition comprises capsicum comprisingcapsaicin, dihydrocapsaicin, and nordihydrocapsaicin, feverfew extract,eucalyptol, peppermint oil, rosemary extract, vegetable glycerin,ascorbic acid, citric acid, and sea salt. An embodiment may comprisepotassium sorbate at a concentration of about 0.05% to about 0.30% w/w.

The feverfew extract relieves and prevents headache symptoms. Theeucalyptol is used to ameliorate the sensory experience and soothe thenasal mucosa. The peppermint oil relieves and helps prevent headachesymptoms. The rosemary extract is an anti-microbial agent and a naturalpreservative which protects and stabilizes the headache reliefcomposition. In a surprising and unexpected result, the rosemary extractwas also found to make the sensory experience due to the presence ofcapsicum in the composition more tolerable to the user, withoutnegatively affecting the efficacy of the composition. The vegetableglycerin is a moisturizer, assists the capsaicinoids contained in thecapsicum to maintain its potency and effectiveness for longer periods oftime, shortens the length of time of the burning sensation associatedwith the capsaicinoids in the capsicum without reducing itseffectiveness, and stabilizes the formula. The ascorbic acid adjusts thepH supports the immune system, and acts as a natural preservative. Thecitric acid further adjusts the pH level and stabilizes the formula. Anyother suitable pH modulator may be used to adjust and/or maintain the pHof the composition. The sea salt acts as a nasal cavity cleanser whichhelps flush out bacteria, and dried or clogged mucous which can affectthe performance of nerve receptors in the trigeminal region.

In another embodiment of the present invention, the headache reliefcomposition may be homeopathic wherein the eucalyptol is used toameliorate the sensory experience and soothe the nasal mucosa, and thefeverfew extract is for headache relief. Furthermore, the headacherelief composition may include both eucalyptol and feverfew extract as atincture.

In still another embodiment of the present invention, the headacherelief composition may include between about 0.0044% to 0.0047% byweight of the total water weight of capsicum comprising, but not limitedto, capsaicin, dihydrocapsaicin, and nordihydrocapsaicin, or about 0.7to about 1.5 ppm total capsaicinoids.

One example of the headache relief composition in accordance with anembodiment of the present invention in 5 gallons of purified waterincludes:

0.0044% to 0.0047% by weight of the total water weight of capsicum;

0.10% by weight of the total water weight of feverfew extract;

0.0027% by weight of the total water weight of peppermint oil;

0.13% by weight of the total water weight of eucalyptol;

0.08% by weight of the total water weight of rosemary extract;

3.65% by weight of the total water weight of vegetable glycerin;

0.53% by weight of the total water weight of sea salt;

0.83% by weight of the total water weight of ascorbic acid;

0.26% by weight of the total water weight of citric acid.

In another embodiment, the headache relief composition may beadministered as a preventative and symptomatic tool. In one embodimentthe composition may further comprise from about 0.05% to about 0.30% w/wor about 0.12% by weight of the total water weight of potassium sorbate.

Example 4

Another example of the present invention relates to an allergy reliefcomposition. The allergy relief composition provides relief of symptomscaused by allergies such as nasal congestion, sinus pressure, andheadaches. The allergy relief composition includes capsicum comprisingcapsaicin, dihydrocapsaicin, and nordihydrocapsaicin, nettle extract,eucalyptol, rosemary extract, vegetable glycerin, ascorbic acid, citricacid, and sea salt.

The nettle extract helps relieve and desensitize allergy symptoms andrelated allergy triggers. The eucalyptol is used to ameliorate thesensory experience and soothe the nasal mucosa. The rosemary extract isan anti-microbial agent and a natural preservative which protects andstabilizes the allergy relief composition. In a surprising andunexpected result, the rosemary extract was also found to make thesensory experience due to the presence of capsicum in the compositionmore tolerable to the user, without negatively affecting the efficacy ofthe composition. The vegetable glycerin is a moisturizer, assists thecapsaicinoids contained in the capsicum to maintain their potency andeffectiveness for longer periods of time, shortens the length of time ofthe burning sensation associated with the capsaicinoids in the capsicumwithout reducing its effectiveness, and stabilizes the formula. Theascorbic acid adjusts the pH level, supports the immune system, and actsas a natural preservative. The citric acid adjusts the pH level andstabilizes the formula. Any other suitable pH modulator may be used toadjust and/or maintain the pH of the composition. The sea salt acts as anasal cavity cleanser which helps flush out bacteria, and dried orclogged mucous therefrom. The potassium sorbate may be used as apreservative.

In another embodiment of the present invention, the allergy reliefcomposition may be homeopathic wherein the eucalyptol is used toameliorate the sensory experience and soothe the nasal mucosa.Furthermore, the homeopathic allergy relief composition may includeeucalyptol as a tincture and nettle extract as a tincture.

In still another embodiment of the present invention, the allergy reliefcomposition may include between about 0.0029% to 0.0032% by weight ofthe total water weight of capsicum comprising capsaicin,dihydrocapsaicin, and nordihydrocapsaicin, providing about 0.4 to about0.5 ppm total capsaicinoids.

Another embodiment of the allergy relief composition in 5 gallons ofpurified water includes:

0.0029% to 0.0032% by weight of the total water weight of capsicum;

0.10% by weight of the total water weight of nettle extract;

0.13% by weight of the total water weight of eucalyptol;

0.08% by weight of the total water weight of rosemary extract;

3.65% by weight of the total water weight of vegetable glycerin;

0.53% by weight of the total water weight of sea salt;

0.83% by weight of the total water weight of ascorbic acid; and

0.26% by weight of the total water weight of citric acid.

In another embodiment, the allergy relief composition may beadministered as a preventative and symptomatic tool. In an embodiment,the composition may further comprise potassium sorbate at aconcentration of about 0.05% to about 0.30% w/w.

Example 5

Another example of the present invention relates to a cold reliefcomposition. The cold relief composition prevents and provides relief ofsymptoms caused by colds, flu, and poor immune system performance. Thecold relief composition comprises capsicum including, but not limitedto, capsaicin, dihydrocapsaicin, and nordihydrocapsaicin, echinaceaextract, eucalyptol, golden seal extract, spearmint oil, vegetableglycerin, ascorbic acid, citric acid and sea salt.

The echinacea extract and the golden seal extract support the immunesystem. The eucalyptol is used to ameliorate the sensory experience andsoothe the nasal mucosa. The spearmint oil provides a sweet taste. Thevegetable glycerin is a moisturizer, assists the capsaicinoids containedin the capsicum to maintain its potency and effectiveness for longerperiods of time, shortens the length of time of the burning sensationassociated with the capsaicinoids in the capsicum without reducing itseffectiveness, and stabilizes the formula. The ascorbic acid adjusts thepH level, supports the immune system, and acts as a naturalpreservative. The citric acid adjusts the pH level and stabilizes theformula. Any other suitable pH modulator may be used to adjust and/ormaintain the pH of the composition. The sea salt acts as a naturalpreservative.

In another embodiment of the present invention, the cold reliefcomposition may be homeopathic wherein the eucalyptol is used toameliorate the sensory experience and soothe the nasal mucosa, and theechinacea extract and golden seal extract provide immune system support.Furthermore, the homeopathic cold relief composition may includeeucalyptol as a tincture, echinacea extract as a tincture, and goldenseal extract as a tincture.

In still another embodiment of the present invention, the cold reliefcomposition may comprise between about 0.0024% to 0.0027% by weight ofthe total water weight of capsicum comprising capsaicin,dihydrocapsaicin, and nordihydrocapsaicin, providing about 0.3 to about0.7 ppm total capsaicinoids.

One example of the cold relief composition in accordance with anembodiment of the present invention in 5 gallons of purified waterincludes:

0.0024% to 0.0027% by weight of the total water weight of capsicum;

0.20% by weight of the total water weight of echinacea extract;

0.13% by weight of the total water weight of eucalyptol;

0.15% by weight of the total water weight of golden seal extract;

0.013% by weight of the total water weight of spearmint oil;

0.53% by weight of the total water weight of sea salt;

3.65% by weight of the total water weight of vegetable glycerin;

0.83% by weight of the total water weight of ascorbic acid; and

0.26% by weight of the total water weight of citric acid.

In another embodiment, the cold relief composition may be administeredbefore coming into contact with potential germs such as crowdedenvironments, malls, schools, and airplanes.

While in the foregoing specification this invention has been describedin relation to certain preferred embodiments thereof, and many detailshave been set forth for the purpose of illustration, it will be apparentto those skilled in the art that the invention is susceptible toadditional embodiments and that certain details described herein can bevaried considerably without departing from the basic principles of theinvention.

What is claimed is:
 1. A method of intranasal treatment of nasalsymptoms in a human in need thereof consisting essentially of the stepsof: (a) administering intranasally from an intranasal spray container acomposition consisting essentially of a capsicum extract at aconcentration of about 0.00060% to about 0.010% w/w, a rosemary extractat a concentration of about 0.02% to about 0.25% w/w, a eucalyptolextract at a concentration of about 0.07% to about 0.15% w/w, vegetableglycerin at a concentration of about 3.5% to about 5.0% w/w, ascorbicacid at a concentration of about 0.10% to about 0.90% w/w, sea salt at aconcentration of about 0.40% to about 1.2% w/w, and potassium sorbate ata concentration of about 0.05% to about 0.3% to a human in need thereof;and (b) wherein said administration provides relief to the human in needthereof from at least one symptom selected from the group consisting ofnasal congestion, sinus pressure, headache, sinus pain and acombinations thereof.